Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms
Open accessThe DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.
Abstract
Glycosylation of the conserved asparagine residue in each heavy chain of IgG in the CH2 domain is known as N-glycosylation. It is one of the most common post-translational modifications and important critical quality attributes of monoclonal antibody (mAb) therapeutics. Various studies have demonstrated the effects of the Fc N-glycosylation on safety, Fc effector functions, and pharmacokinetics, both dependent and independent of neonatal Fc receptor (FcRn) pathway. However, separation of various glycoforms to investigate the biological and functional relevance of glycosylation is a major challenge, and existing studies often discuss the overall impact of N-glycans, without considering the individual contributions of each glycoform when evaluating mAbs with highly heterogeneous distributions. In this study, chemoenzymatic glycoengineering incorporating an endo-β-N-acetylglucosaminidase (ENGase) EndoS2 and its mutant with transglycosylation activity was used to generate mAb glycoforms with highly homogeneous and well-defined N-glycans to better understand and precisely evaluate the effect of each N-glycan structure on Fc effector functions and protein stability. We demonstrated that the core fucosylation, non-reducing terminal galactosylation, sialylation, and mannosylation of IgG1 mAb N-glycans impact not only on FcγRIIIa binding, antibody-dependent cell-mediated cytotoxicity, and C1q binding, but also FcRn binding, thermal stability and propensity for protein aggregation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures














Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“while increased galactosylation can enhance C1q and CDC.”
From Impact of process parameters on IgG glycosylation in CHO systems: a comprehensive quantitative analysis (2026) · cites this paper as [76]
The cited source says what the claim attributes to it.
In the citing paper
“For cytotoxic IgG1, lower core fucose generally improve FcγRIIIa binding and ADCC”
From Impact of process parameters on IgG glycosylation in CHO systems: a comprehensive quantitative analysis (2026) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346 · cited 2×
“FcRn is expressed in several organs and tissues.(17) It binds to IgGs under acidic conditions, leading to IgG internalization into the endosome either by pinocytosis or endocytosis.”
BackgroundShields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Post-translational modifications in the context of therapeutic proteins
Walsh, G., & Jefferis, R. (2006) · Nature Biotechnology · doi:10.1038/nbt1252 · Cited by 1,005
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc
Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C., & Ravetch, J. V. (2008) · Science · doi:10.1126/science.1154315 · Cited by 849
Properties of mouse and human IgG receptors and their contribution to disease models
Bruhns, P. (2012) · Blood · doi:10.1182/blood-2012-01-380121 · Cited by 847
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837 · cited 1×
“such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).(8) Both ADCC and CDC activities induce cytotoxicity through the lysis of target cells.”
BackgroundThe Thermal Stability of Immunoglobulin: Unfolding and Aggregation of a Multi-Domain Protein
Vermeer, A. W. P., & Norde, W. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76602-1 · Cited by 666
Enhanced antibody half-life improves in vivo activity
Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I. W. L., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1601 · Cited by 653 · cited 1×
“Modulation of the binding affinity to FcRn has been shown to enhance antibody halflife in vivo.(20) N-glycosylation independent of FcRn interaction has also been described to affect the PK profile due to interactions with the endocytic mannose receptor.”
BackgroundThe function of Fcγ receptors in dendritic cells and macrophages
Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H., & Lambrecht, B. N. (2014) · Nature Reviews Immunology · doi:10.1038/nri3582 · Cited by 639
Protein quality control in the early secretory pathway
Anelli, T., & Sitia, R. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601974 · Cited by 623 · cited 1×
“N-glycosylation is known to have a variety of roles, including protein quality control, in a secretory pathway.(2) In the endoplasmic reticulum, the precise control of N-glycosylation by defined enzymes is the key to distinguishing between the correctly and incorrectly folded proteins.”
BackgroundMouse and human FcR effector functions
Bruhns, P., & Jönsson, F. (2015) · Immunological Reviews · doi:10.1111/imr.12350 · Cited by 579
Yamane‐Ohnuki, N., Kinoshita, S., Inoue‐Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., Wakitani, M., Niwa, R., Sakurada, M., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20151 · Cited by 572 · cited 2×
“Enhanced ADCC activity in biotherapeutics has been previously achieved through the removal of core fucosylation with α-1,6 linkage via controlled cell culture processes.(12) CDC activity is also known to be affected by N-glycosylation,(13,14) which is activated by the binding of complement component C1q to the Fc regi…”
BackgroundMethodTerminal sugars of Fc glycans influence antibody effector functions of IgGs
Raju, T. S. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.007 · Cited by 521 · cited 2×
“Our observations for core defucosylation were supported by many previous studies investigating both heterogeneous and homogeneous glycoforms.(12,13,22,34-42) However, no consensus Figure 8.”
BackgroundMethodLiu, J. K. H. (2014) · Annals of Medicine & Surgery · doi:10.1016/j.amsu.2014.09.001 · Cited by 515
Scallon, B. J., Tam, S. H., McCarthy, S. G., Cai, A. N., & Raju, T. S. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.09.005 · Cited by 396
Control of Recombinant Monoclonal Antibody Effector Functions by Fc N‐Glycan Remodeling in Vitro
Hodoniczky, J., Zheng, Y. Z., & James, D. C. (2005) · Biotechnology Progress · doi:10.1021/bp050228w · Cited by 393
Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding
Houde, D., Peng, Y., Berkowitz, S. A., & Engen, J. R. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900540-mcp200 · Cited by 393 · cited 1×
“Previous studies have supported the stabilizing effect of terminal galactosylation, with collective evidence indicating that the terminal galactose of N-glycan, especially the α-1,3-galactose, interacts with Lys246 of the CH2 domain.(43) More hydrogen bonds between sugar residues and amino acids are formed with termin…”
BackgroundPharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liu, L. (2018) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 390 · cited 2×
“This process is important in pharmacokinetics (PK) as a key part of regulating serum persistence.(16) FcRn is expressed in several organs and tissues.”
BackgroundKanda, Y., Yamada, T., Mori, K., Okazaki, A., Inoue, M., Kitajima-Miyama, K., Kuni-Kamochi, R., Nakano, R., Yano, K., Kakita, S., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwl057 · Cited by 372
Dekkers, G., Treffers, L., Plomp, R., Bentlage, A. E. H., de Boer, M., Koeleman, C. A. M., Lissenberg-Thunnissen, S. N., Visser, R., Brouwer, M., Mok, J. Y., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00877 · Cited by 356
IgG Fc engineering to modulate antibody effector functions
Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356
The Carbohydrate at FcγRIIIa Asn-162
Ferrara, C., Stuart, F., Sondermann, P., Brünker, P., & Umaña, P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510171200 · Cited by 354 · cited 1×
“FcγRIIIa has five putative N-glycosylation sites, and those N-glycosylations at Asn-162 and Asn-45 have been reported to be key regulators of IgG-Fc binding.(54,55) To the best of our knowledge, however, no reports have indicated that each one of those amino acid mutations modulate IgG-Fc binding.”
BackgroundImpact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350 · cited 1×
“Closely related to the protein stability, the propensity towards protein aggregation is another important attribute that can be caused by protein instability, and it also needs to be considered because of the risk of immunogenicity.(26,27) Despite the recent efforts to elucidate the effect of the N-glycan on various a…”
BackgroundThe impact of glycosylation on monoclonal antibody conformation and stability
Zheng, K., Bantog, C., & Bayer, R. (2011) · mAbs · doi:10.4161/mabs.3.6.17922 · Cited by 342
N-Linked Protein Glycosylation in the Endoplasmic Reticulum
Breitling, J., & Aebi, M. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a013359 · Cited by 332 · cited 1×
“This heterogeneity is due to the different glycosyltransferase levels and gene expression profile in addition to the availability and spatial localization of nucleotide-sugar substrates in the cytoplasm.(3) N-glycosylation of mAbs is most frequently formed at a conserved asparagine residue located in the heavy chain c…”
BackgroundMimura, Y., Church, S., Ghirlando, R., Ashton, P. R., Dong, S., Goodall, M., Lund, J., & Jefferis, R. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(00)00105-x · Cited by 329
Modulating IgG effector function by Fc glycan engineering
Li, T., DiLillo, D. J., Bournazos, S., Giddens, J. P., Ravetch, J. V., & Wang, L.-X. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1702173114 · Cited by 322
Contribution of Variable Domains to the Stability of Humanized IgG1 Monoclonal Antibodies
Ionescu, R. M., Vlasak, J., Price, C., & Kirchmeier, M. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21104 · Cited by 313 · cited 1×
“transitions(32) indicative of the unfolding of their various domains, and our peak assignments were based on previous reports of the thermal transitions of IgG1 antibodies.(33) The first transition peak corresponds to the unfolding of the CH2 domain, and the other two consecutive peaks represent unfolding of the antig…”
BackgroundAdvances in the assessment and control of the effector functions of therapeutic antibodies
Jiang, X.-R., Song, A., Bergelson, S., Arroll, T., Parekh, B., May, K., Chung, S., Strouse, R., Mire-Sluis, A., & Schenerman, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3365 · Cited by 299 · cited 1×
“There are three classes of mAb mechanisms of action based on the type of antigen: 1) cellbound antigen with depletion caused by Fc effector function; 2) cell-bound antigen with blocking or agonist activity caused by binding; and 3) soluble antigen with blocking caused by binding.(6) Studies show that glycosylation is…”
BackgroundBoyd, P. N., Lines, A. C., & Patel, A. K. (1995) · Molecular Immunology · doi:10.1016/0161-5890(95)00118-2 · Cited by 283
Anti‐N‐glycolylneuraminic acid antibodies identified in healthy human serum
Zhu, A., & Hurst, R. (2002) · Xenotransplantation · doi:10.1034/j.1399-3089.2002.02138.x · Cited by 273 · cited 1×
“Specific glycan linkages such as galactose-α-1,3-galactose and certain types of sialic acid such as N-glycolylneuraminic acid (NGNA) have been reported to induce hypersensitivity reactions.(24,25) Although the numerous studies pertaining to IgG glycosylation have focused on attributes such as safety, efficacy, and pha…”
BackgroundJoubert, M. K., Hokom, M., Eakin, C., Zhou, L., Deshpande, M., Baker, M. P., Goletz, T. J., Kerwin, B. A., Chirmule, N., Narhi, L. O., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.330902 · Cited by 268
Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity
Nimmerjahn, F., Anthony, R. M., & Ravetch, J. V. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702936104 · Cited by 253
The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy
Sockolosky, J. T., & Szoka, F. C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.02.005 · Cited by 235
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells
Peipp, M., Lammerts van Bueren, J. J., Schneider-Merck, T., Bleeker, W. W. K., Dechant, M., Beyer, T., Repp, R., van Berkel, P. H. C., Vink, T., van de Winkel, J. G. J., et al. (2008) · Blood · doi:10.1182/blood-2008-03-144600 · Cited by 222 · cited 1×
“Our evaluations of the effects of terminal sialylation in FcγRIIIa binding analysis by SPR and ADCC reporter bioassay using N-glycosylated ligand agree with previous reports that have described reduction of FcγRIIIa affinity,(13,38,40,46,49,50) but found no evidence of an unchanged affinity as previously reported.(30,…”
ResultIn vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity
Thomann, M., Schlothauer, T., Dashivets, T., Malik, S., Avenal, C., Bulau, P., Rüger, P., & Reusch, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134949 · Cited by 220 · cited 1×
“Our evaluations of the effects of terminal sialylation in FcγRIIIa binding analysis by SPR and ADCC reporter bioassay using N-glycosylated ligand agree with previous reports that have described reduction of FcγRIIIa affinity,(13,38,40,46,49,50) but found no evidence of an unchanged affinity as previously reported.(30,…”
ResultPeschke, B., Keller, C. W., Weber, P., Quast, I., & Lünemann, J. D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00646 · Cited by 219
Therapeutic antibodies: past, present and future
Leavy, O. (2010) · Nature Reviews Immunology · doi:10.1038/nri2763 · Cited by 215
Yamaguchi, Y., Nishimura, M., Nagano, M., Yagi, H., Sasakawa, H., Uchida, K., Shitara, K., & Kato, K. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.10.002 · Cited by 204
Yu, M., Brown, D., Reed, C., Chung, S., Lutman, J., Stefanich, E., Wong, A., Stephan, J.-P., & Bayer, R. (2012) · mAbs · doi:10.4161/mabs.20737 · Cited by 203 · cited 2×
“For C1q binding, the effect of core fucosylation and terminal mannosylation observed in our study was consistent with previous studies, where core fucosylation had no impact(12,22,35,56) and highmannose glycoform showed impaired binding.(21,23,45,57) However, the effect of terminal galactosylation for C1q binding Tabl…”
MethodResultA common glycan structure on immunoglobulin G for enhancement of effector functions
Lin, C.-W., Tsai, M.-H., Li, S.-T., Tsai, T.-I., Chu, K.-C., Liu, Y.-C., Lai, M.-Y., Wu, C.-Y., Tseng, Y.-C., Shivatare, S. S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513456112 · Cited by 200
Wright, A., & Morrison, S. L. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.3.1087 · Cited by 192 · cited 2×
“For C1q binding, the effect of core fucosylation and terminal mannosylation observed in our study was consistent with previous studies, where core fucosylation had no impact(12,22,35,56) and highmannose glycoform showed impaired binding.(21,23,45,57) However, the effect of terminal galactosylation for C1q binding Tabl…”
BackgroundResultZhou, Q., Shankara, S., Roy, A., Qiu, H., Estes, S., McVie‐Wylie, A., Culm‐Merdek, K., Park, A., Pan, C., & Edmunds, T. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21598 · Cited by 184 · cited 1×
“For C1q binding, the effect of core fucosylation and terminal mannosylation observed in our study was consistent with previous studies, where core fucosylation had no impact(12,22,35,56) and highmannose glycoform showed impaired binding.(21,23,45,57) However, the effect of terminal galactosylation for C1q binding Tabl…”
ResultZhou, X., Hu, W., & Qin, X. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0089 · Cited by 178 · cited 1×
“This process results in the cleavage of complements C4 and C3 and activates the membrane attack complex.(15) Another important Fc effector function is the mediation of the IgG serum recycling pathway through interactions with the neonatal Fc receptor (FcRn).”
BackgroundBrader, M. L., Estey, T., Bai, S., Alston, R. W., Lucas, K. K., Lantz, S. R., Landsman, P., & Maloney, K. M. (2015) · Molecular Pharmaceutics · doi:10.1021/mp400666b · Cited by 159
Wright, A., & Morrison, S. L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3393 · Cited by 158 · cited 2×
“For C1q binding, the effect of core fucosylation and terminal mannosylation observed in our study was consistent with previous studies, where core fucosylation had no impact(12,22,35,56) and highmannose glycoform showed impaired binding.(21,23,45,57) However, the effect of terminal galactosylation for C1q binding Tabl…”
BackgroundResultLi, T., Tong, X., Yang, Q., Giddens, J. P., & Wang, L. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.738765 · Cited by 137 · cited 1×
“highly homogeneous glycoforms generated by chemoenzymatic glycoengineering.(28)”
Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies
Schlothauer, T., Rueger, P., Stracke, J. O., Hertenberger, H., Fingas, F., Kling, L., Emrich, T., Drabner, G., Seeber, S., Auer, J., et al. (2013) · mAbs · doi:10.4161/mabs.24981 · Cited by 136 · cited 1×
“FcRn affinity chromatography utilized a human FcRn prepacked column (Roche Custom Biotech, Cat # 08128057001).(31,74) According to the manufacturer, FcRn is recombinantly expressed by a CHO cell line, thus one putative N-glycosylation site is present (UniProt accession number P55899), although the glycosylation patter…”
MethodChung, S., Quarmby, V., Gao, X., Ying, Y., Lin, L., Reed, C., Fong, C., Lau, W., Qiu, Z. J., Shen, A., et al. (2012) · mAbs · doi:10.4161/mabs.19941 · Cited by 127
Shibata-Koyama, M., Iida, S., Okazaki, A., Mori, K., Kitajima-Miyama, K., Saitou, S., Kakita, S., Kanda, Y., Shitara, K., Kato, K., et al. (2008) · Glycobiology · doi:10.1093/glycob/cwn110 · Cited by 118
Sjögren, J., Struwe, W. B., Cosgrave, E. F. J., Rudd, P. M., Stervander, M., Allhorn, M., Hollands, A., Nizet, V., & Collin, M. (2013) · Biochemical Journal · doi:10.1042/bj20130126 · Cited by 115
Ghirlando, R., Lund, J., Goodall, M. D., & Jefferis, R. (1999) · Immunology Letters · doi:10.1016/s0165-2478(99)00029-2 · Cited by 115
Multi-angle effector function analysis of human monoclonal IgG glycovariants
Dashivets, T., Thomann, M., Rueger, P., Knaupp, A., Buchner, J., & Schlothauer, T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143520 · Cited by 101 · cited 2×
“Affinity chromatography For pH gradient human FcRn affinity chromatography, sialylated and galactosylated glycoforms showed longer retention time compared to terminal agalactosylated species (mAb-FA 2G0 and mAb-A2G0) which is consistent with previous reports.(30,31) Partially deglycosylated glycoforms showed shorter r…”
ResultKurogochi, M., Mori, M., Osumi, K., Tojino, M., Sugawara, S.-I., Takashima, S., Hirose, Y., Tsukimura, W., Mizuno, M., Amano, J., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0132848 · Cited by 96
Noguchi, M., Fujieda, T., Huang, W. C., Ishihara, M., Kobayashi, A., & Shoda, S. (2012) · Helvetica Chimica Acta · doi:10.1002/hlca.201200414 · Cited by 94
Influence of glycosylation pattern on the molecular properties of monoclonal antibodies
Zheng, K., Yarmarkovich, M., Bantog, C., Bayer, R. J., & Patapoff, T. W. (2014) · mAbs · doi:10.4161/mabs.28588 · Cited by 81 · cited 1×
“The IgG molecule with high mannose glycan showed remarkably decreased Tm CH2 and Tm FS, and could impact the aggregation propensity demonstrated in this and previous reports.(66,67) The reduced stability and increased aggregation propensity of high mannose glycoforms are likely closely related to the structural integr…”
BackgroundCrystallizable Fragment Glycoengineering for Therapeutic Antibodies Development
Li, W., Zhu, Z., Chen, W., Feng, Y., & Dimitrov, D. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01554 · Cited by 78
Kiyoshi, M., Caaveiro, J. M. M., Tada, M., Tamura, H., Tanaka, T., Terao, Y., Morante, K., Harazono, A., Hashii, N., Shibata, H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22199-8 · Cited by 77 · cited 2×
“× 75 mm, TSKgel FcR-IIIA-NPR).(53) FcγRIIIa ligand 368 R.”
Glycosylation of IgG-Fc: a molecular perspective
Kiyoshi, M., Tsumoto, K., Ishii-Watabe, A., & Caaveiro, J. M. M. (2017) · International Immunology · doi:10.1093/intimm/dxx038 · Cited by 73 · cited 1×
“Glycan-glycan interactions were previously reported to affect the hydrodynamic radius of the antibody.(13,61,68) In our observation, partial deglycosylation, core defucosylation, and terminal sialylation all showed the shortened retention of the main peak, whereas galactosylation with longer retention in the SEC analy…”
BackgroundLi, C., Zhu, S., Ma, C. D., & Wang, L. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b07906 · Cited by 62
Fang, J. S., Richardson, J., Du, Z., & Zhang, Z. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01323 · Cited by 55 · cited 1×
“The IgG molecule with high mannose glycan showed remarkably decreased Tm CH2 and Tm FS, and could impact the aggregation propensity demonstrated in this and previous reports.(66,67) The reduced stability and increased aggregation propensity of high mannose glycoforms are likely closely related to the structural integr…”
BackgroundSchermeyer, M.-T., Wöll, A. K., Kokke, B., Eppink, M., & Hubbuch, J. (2017) · mAbs · doi:10.1080/19420862.2017.1338222 · Cited by 54
Interactions of IgG1 CH2 and CH3 Domains with FcRn
Ying, T., Ju, T. W., Wang, Y., Prabakaran, P., & Dimitrov, D. S. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00146 · Cited by 42
Dynamic Fluctuations of Protein-Carbohydrate Interactions Promote Protein Aggregation
Voynov, V., Chennamsetty, N., Kayser, V., Helk, B., Forrer, K., Zhang, H., Fritsch, C., Heine, H., & Trout, B. L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008425 · Cited by 42
Chen, C.-L., Hsu, J.-C., Lin, C., Wang, C.-H., Tsai, M.-H., Wu, C., Wong, C., & Ma, C. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00140 · Cited by 42
Shivatare, S. S., Huang, L., Zeng, Y., Liao, J.-Y., You, T.-H., Wang, S., Cheng, T., Chiu, C.-W., Chao, P., Chen, L.-T., et al. (2018) · Chemical Communications · doi:10.1039/c8cc03384f · Cited by 37
Consequences of glycan truncation on Fc structural integrity
Buck, P. M., Kumar, S., & Singh, S. K. (2013) · mAbs · doi:10.4161/mabs.26453 · Cited by 35 · cited 1×
“Glycan-glycan interactions were previously reported to affect the hydrodynamic radius of the antibody.(13,61,68) In our observation, partial deglycosylation, core defucosylation, and terminal sialylation all showed the shortened retention of the main peak, whereas galactosylation with longer retention in the SEC analy…”
BackgroundN-Linked Glycan Structures of the Human Fcγ Receptors Produced in NS0 Cells
Cosgrave, E. F. J., Struwe, W. B., Hayes, J. M., Harvey, D. J., Wormald, M. R., & Rudd, P. M. (2013) · Journal of Proteome Research · doi:10.1021/pr400344h · Cited by 31 · cited 1×
“FcγRIIIa Recombinant human FcγRIIIa-V158 used in the SPR analysis was expressed in mouse myeloma cell line and His-tagged on their C-terminal with five putative N-glycosylation sites (NS0derived, Gly17-Gln208, R&D Systems, Cat # 4325-FC-050, GenBank accession number AAH17865), N-glycosylation profile of FcγRIIIa from…”
MethodHiguchi, Y., Eshima, Y., Huang, Y., Kinoshita, T., Sumiyoshi, W., Nakakita, S.-I., & Takegawa, K. (2016) · Biotechnology Letters · doi:10.1007/s10529-016-2230-0 · Cited by 28 · cited 1×
“Preparation steps were essentially as described previously.(71,72) Briefly, α-2,6-sialylglycopeptide was isolated from hen’s egg yolk, and subsequently each asialoglycopeptide and agalactoglycopeptide was obtained by enzymatic truncation of each of two sialic acids and galactoses, followed by oxazoline formation.”
MethodShivatare, S. S., Huang, L., Zeng, Y., Liao, J.-Y., You, T.-H., Wang, S., Cheng, T., Chiu, C.-W., Chao, P., Chen, L.-T., et al. (2018) · Chemical Communications · doi:10.1039/c8cc90292e · Cited by 21
Tsukimura, W., Kurogochi, M., Mori, M., Osumi, K., Matsuda, A., Takegawa, K., Furukawa, K., & Shirai, T. (2017) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2017.1394813 · Cited by 19
Cymer, F., Schlothauer, T., Knaupp, A., & Beck, H. (2017) · Bioanalysis · doi:10.4155/bio-2017-0109 · Cited by 18
Kinetics and Characterization of Non-enzymatic Fragmentation of Monoclonal Antibody Therapeutics
Ravuluri, S., Bansal, R., Chhabra, N., & Rathore, A. S. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2415-4 · Cited by 17 · cited 1×
“A previous report showed that high temperature (50 °C)-induced fragmentation was confirmed to occur by cleavage of the hinge region to form Fab-Fc and Fab/Fc fragments.(70) We hypothesize that the longterm thermal stressed condition did not have major effects on fragmentation derived from the hinge region, and that pe…”
Background
Cited by
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 316
“Overabundance of galactosylation on IgG1 Fc also improved thermostability when measured by differential scanning calorimetry (99).”
BackgroundAggregation of Protein Therapeutics Enhances Their Immunogenicity: Causes and Mitigation Strategies
Lundahl, M. L. E., Fogli, S., Colavita, P. E., & Scanlan, E. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00067e · Cited by 212
Monitoring of immunoglobulin N- and O-glycosylation in health and disease
de Haan, N., Falck, D., & Wuhrer, M. (2019) · Glycobiology · doi:10.1093/glycob/cwz048 · Cited by 129
Highly Selective β-Mannosylations and β-Rhamnosylations Catalyzed by Bis-thiourea
Li, Q., Levi, S. M., & Jacobsen, E. N. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c04255 · Cited by 121
Sialylation as an Important Regulator of Antibody Function
Vattepu, R., Sneed, S. L., & Anthony, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.818736 · Cited by 118
Metadata
- Authors
- Wada, R., Matsui, M., & Kawasaki, N.
- Affiliations
- Astellas Pharma (Japan) (JP)
- Yokohama City University (JP)
- Corresponding author
- Wada, Ryuta
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2018-12-10
- Volume
- 11
- Issue
- 2
- Pages
- 350-372
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- PMC
- PMC6380427
- OpenAlex
- W2901207337
- Cited by
- 186
- References
- 77
- Citations by year
- 2026: 27 · 2025: 25 · 2024: 20 · 2023: 18 · 2022: 26 · 2021: 34 · 2020: 26 · 2019: 10
- FWCI
- 12.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- mAbs (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- funded by Astellas Pharma, Inc
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Keywords
- N-glycosylation, IgG1 monoclonal antibody, glycoengineering, Fc effector functions, FcγRIIIa binding, antibody-dependent cellular cytotoxicity, C1q binding, FcRn binding, thermal stability, protein aggregation, core fucosylation, sialylation, galactosylation, mannosylation, N-glycan structure
- MeSH terms
- Antibodies, Monoclonal, Glycosylation, Humans, Immunoglobulin G, Immunoglobulin Fc Fragments, Polysaccharides, Protein Stability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.